Skip to main content
Erschienen in: General Thoracic and Cardiovascular Surgery 10/2023

15.04.2023 | Original Article

Therapeutic strategy aiming at R0 resection for borderline-resectable esophageal squamous cell carcinoma using induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil

verfasst von: Masanobu Nakajima, Hiroto Muroi, Maiko Kikuchi, Tsukasa Kubo, Noboru Inoue, Keisuke Ihara, Masatoshi Nakagawa, Shinji Morita, Takatoshi Nakamura, Kazuyuki Kojima

Erschienen in: General Thoracic and Cardiovascular Surgery | Ausgabe 10/2023

Einloggen, um Zugang zu erhalten

Abstract

Objective

Treatment for borderline resectable (cT3br) esophageal squamous cell carcinoma (SCC) is currently undefined. This study aimed to analyze the outcome of treatment strategies including induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) against T3br esophageal SCC.

Methods

A total of 32 patients with cT3br esophageal SCC enrolled in this study were treated with two cycles of DCF induction therapy.

Results

The overall response rate to DCF induction therapy was 62.5%, while the disease control rate was 93.8% (complete response (CR), three; partial response (PR), 17; stable disease (SD), 10; progressive disease (PD), 2). After DCF induction chemotherapy, 27 patients underwent conversion surgery (CS) and five patients underwent definitive chemoradiotherapy (CRT). Out of 27 patients who underwent CS, 17 underwent transthoracic esophagectomy and 10 underwent thoracoscopic esophagectomy. Anastomotic leakage occurred in five patients (18.5%) and pneumonia in four (14.8%). Recurrent laryngeal nerve paralysis and arrhythmia were observed in two patients (7.4%). The R0 resection rate was 81.5%. Among the five patients who underwent definitive CRT, only one patient (20.0%) achieved CR. Two patients (40.0%) had PR and two (40.0%) had PD. Salvage esophagectomy was performed in one patient after definitive CRT. The 1-, 3-, and 5-year overall survival rates were 75.0, 50.6, and 46.4%, respectively, whereas the 1-, 3-, and 5-year disease-free survival rates were 54.9, 38.8, and 38.8%, respectively.

Conclusion

DCF induction therapy and subsequent CS or definitive CRT are promising treatment strategies for cT3br esophageal SCC.
Literatur
2.
Zurück zum Zitat Saddoughi SA, Reinersman JM, Zhukov YO, Taswell J, Mara K, Harmsen SW, et al. Survival after surgical resection of stage IV esophageal cancer. Ann Thorac Surg. 2017;103:261–6.CrossRefPubMed Saddoughi SA, Reinersman JM, Zhukov YO, Taswell J, Mara K, Harmsen SW, et al. Survival after surgical resection of stage IV esophageal cancer. Ann Thorac Surg. 2017;103:261–6.CrossRefPubMed
3.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRefPubMed Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRefPubMed
5.
Zurück zum Zitat Watanabe M, Otake R, Kozuki R, Toihata T, Takahashi K, Okamura A, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surg Today. 2020;50:12–20.CrossRefPubMed Watanabe M, Otake R, Kozuki R, Toihata T, Takahashi K, Okamura A, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surg Today. 2020;50:12–20.CrossRefPubMed
6.
Zurück zum Zitat Lee CC, Soon YY, Vellayappan B, Ho F, Tey JCS. Survival rates and safety associated with chemoradiotherapy followed by surgery and chemoradiotherapy alone for patients with T4 esophageal cancer: a systematic review and meta-analysis. Acta Oncol. 2022;61:738–48.CrossRefPubMed Lee CC, Soon YY, Vellayappan B, Ho F, Tey JCS. Survival rates and safety associated with chemoradiotherapy followed by surgery and chemoradiotherapy alone for patients with T4 esophageal cancer: a systematic review and meta-analysis. Acta Oncol. 2022;61:738–48.CrossRefPubMed
7.
Zurück zum Zitat Yoon HH, Ou FS, Soori GS, Shi Q, Wigle DA, Sticca RP, et al. Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance]). Eur J Cancer. 2021;150:214–23.CrossRefPubMedPubMedCentral Yoon HH, Ou FS, Soori GS, Shi Q, Wigle DA, Sticca RP, et al. Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance]). Eur J Cancer. 2021;150:214–23.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Saeki H, Nakashima Y, Kudou K, Sasaki S, Jogo T, Hirose K, et al. Neoadjuvant chemoradiotherapy for patients with cT3/nearly T4 esophageal cancer: is sarcopenia correlated with postoperative complications and prognosis? World J Surg. 2018;42:2894–901.CrossRefPubMed Saeki H, Nakashima Y, Kudou K, Sasaki S, Jogo T, Hirose K, et al. Neoadjuvant chemoradiotherapy for patients with cT3/nearly T4 esophageal cancer: is sarcopenia correlated with postoperative complications and prognosis? World J Surg. 2018;42:2894–901.CrossRefPubMed
9.
Zurück zum Zitat Hamamoto Y, Nojima M, Aoki Y, Suzuki T, Kawasaki K, Hirata K, et al. Inter-evaluator heterogeneity of clinical diagnosis for locally advanced esophageal squamous cell carcinoma. Esophagus. 2017;14:324–32.CrossRefPubMedPubMedCentral Hamamoto Y, Nojima M, Aoki Y, Suzuki T, Kawasaki K, Hirata K, et al. Inter-evaluator heterogeneity of clinical diagnosis for locally advanced esophageal squamous cell carcinoma. Esophagus. 2017;14:324–32.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Kobayashi K, Kanetaka K, Yoneda A, Kobayashi S, Maruya Y, Isagawa Y, et al. Downstaging and histological effects might be reliable predictors of the efficacy of DOC+CDDP+5-FU (DCF) as neoadjuvant therapy for stage III or borderline resectable esophageal cancer: a single institute experience. J Gastrointest Cancer. 2021;52:582–92.CrossRefPubMed Kobayashi K, Kanetaka K, Yoneda A, Kobayashi S, Maruya Y, Isagawa Y, et al. Downstaging and histological effects might be reliable predictors of the efficacy of DOC+CDDP+5-FU (DCF) as neoadjuvant therapy for stage III or borderline resectable esophageal cancer: a single institute experience. J Gastrointest Cancer. 2021;52:582–92.CrossRefPubMed
11.
Zurück zum Zitat Nakajima M, Muroi H, Kikuchi M, Yamaguchi S, Sasaki K, Tsuchioka T, et al. Salvage esophagectomy combined with partial aortic wall resection following thoracic endovascular aortic repair. Gen Thorac Cardiovasc Surg. 2018;66:736–43.CrossRefPubMed Nakajima M, Muroi H, Kikuchi M, Yamaguchi S, Sasaki K, Tsuchioka T, et al. Salvage esophagectomy combined with partial aortic wall resection following thoracic endovascular aortic repair. Gen Thorac Cardiovasc Surg. 2018;66:736–43.CrossRefPubMed
12.
Zurück zum Zitat Japan Esophageal Society. Japanese classification of esophageal cancer, 11th edition: part II and III. Esophagus. 2017;14:37–65.CrossRef Japan Esophageal Society. Japanese classification of esophageal cancer, 11th edition: part II and III. Esophagus. 2017;14:37–65.CrossRef
13.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed
14.
Zurück zum Zitat Nakajima M, Muroi H, Kikuchi M, Takahashi M, Ihara K, Shida Y, et al. Adverse prognostic factors of advanced esophageal cancer in patients undergoing induction therapy with docetaxel, cisplatin and 5-fluorouracil. Anticancer Res. 2018;38:911–8.PubMed Nakajima M, Muroi H, Kikuchi M, Takahashi M, Ihara K, Shida Y, et al. Adverse prognostic factors of advanced esophageal cancer in patients undergoing induction therapy with docetaxel, cisplatin and 5-fluorouracil. Anticancer Res. 2018;38:911–8.PubMed
15.
Zurück zum Zitat Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRefPubMedPubMedCentral Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, et al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus. 2019;16:1–24.CrossRefPubMed Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, et al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus. 2019;16:1–24.CrossRefPubMed
17.
Zurück zum Zitat Ajani JA, D’Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, et al. NCCN clinical practice guideline in oncology (NCCN guidelinesⓇ) esophageal and esophagogastric junction cancers version 5. www.nccn.org/patients (2022). Accessed 20 Dec 2022. Ajani JA, D’Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, et al. NCCN clinical practice guideline in oncology (NCCN guidelines) esophageal and esophagogastric junction cancers version 5. www.​nccn.​org/​patients (2022). Accessed 20 Dec 2022.
18.
Zurück zum Zitat Suzuki T, Okamura A, Watanabe M, Chin K. ASO author reflections: how should we approach borderline resectable esophageal squamous cell carcinoma? Ann Surg Oncol. 2020;27:1518–9.CrossRefPubMed Suzuki T, Okamura A, Watanabe M, Chin K. ASO author reflections: how should we approach borderline resectable esophageal squamous cell carcinoma? Ann Surg Oncol. 2020;27:1518–9.CrossRefPubMed
19.
Zurück zum Zitat Ishikura S, Kondo T, Murai T, Ozawa Y, Yanagi T, Sugie C, et al. A single-arm, multicenter, phase II clinical study of tislelizumab plus albumin-bound paclitaxel/cisplatin as neoadjuvant therapy for borderline resectable esophageal squamous cell carcinoma. J Radiat Res. 2020;61:464–9.CrossRefPubMedPubMedCentral Ishikura S, Kondo T, Murai T, Ozawa Y, Yanagi T, Sugie C, et al. A single-arm, multicenter, phase II clinical study of tislelizumab plus albumin-bound paclitaxel/cisplatin as neoadjuvant therapy for borderline resectable esophageal squamous cell carcinoma. J Radiat Res. 2020;61:464–9.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Suzuki T, Okamura A, Watanabe M, Mine S, Imamura Y, Asari T, et al. Neoadjuvant chemoradiotherapy with cisplatin plus fluorouracil for borderline resectable esophageal squamous cell carcinoma. Ann Surg Oncol. 2020;27:1510–7.CrossRefPubMed Suzuki T, Okamura A, Watanabe M, Mine S, Imamura Y, Asari T, et al. Neoadjuvant chemoradiotherapy with cisplatin plus fluorouracil for borderline resectable esophageal squamous cell carcinoma. Ann Surg Oncol. 2020;27:1510–7.CrossRefPubMed
21.
Zurück zum Zitat Wang Z, Hu M, Hu Y, Li Q, Wu J, Fong WP, et al. Paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma: a phase II clinical trial. Esophagus. 2022;19:120–8.CrossRefPubMed Wang Z, Hu M, Hu Y, Li Q, Wu J, Fong WP, et al. Paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma: a phase II clinical trial. Esophagus. 2022;19:120–8.CrossRefPubMed
22.
Zurück zum Zitat Shiraishi O, Yasuda T, Kato H, Momose K, Hiraki Y, Yasuda A, et al. Comparison of aggressive planned salvage surgery versus neoadjuvant chemoradiotherapy plus surgery for borderline resectable T4 squamous cell carcinoma. Ann Surg Oncol. 2021;28:6366–75.CrossRefPubMed Shiraishi O, Yasuda T, Kato H, Momose K, Hiraki Y, Yasuda A, et al. Comparison of aggressive planned salvage surgery versus neoadjuvant chemoradiotherapy plus surgery for borderline resectable T4 squamous cell carcinoma. Ann Surg Oncol. 2021;28:6366–75.CrossRefPubMed
23.
Zurück zum Zitat Li X, Xu C, Qiu H, Chen D, Zhu K, Zhang B, et al. A single-arm, multicenter, phase II clinical study of tislelizumab plus albumin-bound paclitaxel/cisplatin as neoadjuvant therapy for borderline resectable esophageal squamous cell carcinoma. Ann Transl Med. 2022;10:263.CrossRefPubMedPubMedCentral Li X, Xu C, Qiu H, Chen D, Zhu K, Zhang B, et al. A single-arm, multicenter, phase II clinical study of tislelizumab plus albumin-bound paclitaxel/cisplatin as neoadjuvant therapy for borderline resectable esophageal squamous cell carcinoma. Ann Transl Med. 2022;10:263.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.CrossRefPubMed Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.CrossRefPubMed
26.
Zurück zum Zitat Hirohata R, Hamai Y, Hihara J, Emi M, Kurokawa T, Yoshikawa T, et al. Evaluation of neoadjuvant chemoradiotherapy followed by surgery for borderline resectable esophageal squamous cell carcinoma. World J Surg. 2022;46:1934–43.CrossRefPubMed Hirohata R, Hamai Y, Hihara J, Emi M, Kurokawa T, Yoshikawa T, et al. Evaluation of neoadjuvant chemoradiotherapy followed by surgery for borderline resectable esophageal squamous cell carcinoma. World J Surg. 2022;46:1934–43.CrossRefPubMed
27.
Zurück zum Zitat Sugase T, Sugimura K, Kanemura T, Takeoka T, Yamamoto M, Shinno N, et al. Recurrence pattern comparing preoperative chemoradiotherapy and preoperative chemotherapy with docetaxel plus 5-fluorouracil and cisplatin for advanced esophageal cancer. Oncology. 2022;100:655–65.CrossRefPubMed Sugase T, Sugimura K, Kanemura T, Takeoka T, Yamamoto M, Shinno N, et al. Recurrence pattern comparing preoperative chemoradiotherapy and preoperative chemotherapy with docetaxel plus 5-fluorouracil and cisplatin for advanced esophageal cancer. Oncology. 2022;100:655–65.CrossRefPubMed
28.
Zurück zum Zitat Makino T, Yamasaki M, Tanaka K, Miyazaki Y, Takahashi T, Kurokawa Y, et al. Treatment and clinical outcome of clinical T4 esophageal cancer: a systematic review. Ann Gastroenterol Surg. 2018;3:169–80.CrossRefPubMedPubMedCentral Makino T, Yamasaki M, Tanaka K, Miyazaki Y, Takahashi T, Kurokawa Y, et al. Treatment and clinical outcome of clinical T4 esophageal cancer: a systematic review. Ann Gastroenterol Surg. 2018;3:169–80.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Yokota T, Kato K, Hamamoto Y, Tsubosa Y, Ogawa H, Ito Y, et al. Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer. 2016;115:1328–34.CrossRefPubMedPubMedCentral Yokota T, Kato K, Hamamoto Y, Tsubosa Y, Ogawa H, Ito Y, et al. Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer. 2016;115:1328–34.CrossRefPubMedPubMedCentral
Metadaten
Titel
Therapeutic strategy aiming at R0 resection for borderline-resectable esophageal squamous cell carcinoma using induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil
verfasst von
Masanobu Nakajima
Hiroto Muroi
Maiko Kikuchi
Tsukasa Kubo
Noboru Inoue
Keisuke Ihara
Masatoshi Nakagawa
Shinji Morita
Takatoshi Nakamura
Kazuyuki Kojima
Publikationsdatum
15.04.2023
Verlag
Springer Nature Singapore
Erschienen in
General Thoracic and Cardiovascular Surgery / Ausgabe 10/2023
Print ISSN: 1863-6705
Elektronische ISSN: 1863-6713
DOI
https://doi.org/10.1007/s11748-023-01934-7

Weitere Artikel der Ausgabe 10/2023

General Thoracic and Cardiovascular Surgery 10/2023 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.